Aclaris lays off 46%, resurrects zunsemetinib for cancer
20 Dec 2023 //
FIERCE BIOTECH
Aclaris Announces Results from 12-Week Phase 2b Trial of Oral Zunsemetinib
13 Nov 2023 //
GLOBENEWSWIRE
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib
13 Jun 2023 //
GLOBENEWSWIRE